Avita's ReCell Spray-On Skin exhibits potential for applications relating to healing of acute wounds

Avita Medical Ltd. (ASX: AVH), the regenerative medicine company, announced today that a clinical study of 18 patients suffering from partial-thickness burns, some of which had failed to heal after treatment with other wound-healing methods ('chronic wounds'), demonstrated successful wound-healing after being treated with ReCell® Spray-On Skin™ from Avita Medical. Results of the study ("Opportunities for ReCell® Autologous Cell Harvesting in Burns and Delayed Healing") were presented last month at the 44th annual meeting of the British Burns Association by principal investigators Rajiv Sood, M.D., Professor of Surgery, Indiana University School of Medicine and Director, Richard M. Fairbanks Burn Center, Wishard Hospital, Indianapolis; and, Isabel Jones, M.D., Consulting Physician, Burns Unit, Chelsea and Westminster Hospital, London.

“However, a rapid autologous material should best be able to integrate with and stimulate the body's natural healing response. Initial results indicate that ReCell Spray-On Skin has potentially broad applications to the healing of acute wounds.”

"Often, wound closure is promoted via use of skin substitutes, cultures or grafts," said Dr. Sood. "However, a rapid autologous material should best be able to integrate with and stimulate the body's natural healing response. Initial results indicate that ReCell Spray-On Skin has potentially broad applications to the healing of acute wounds."

"Our ReCell spray-on regenerative medicine is designed to harness the body's own ability to heal itself and is approved for sale in an easy-to-use bedside kit for clinicians in Australia, France, Germany, Portugal, Russia, The Netherlands and the United Kingdom," said William Dolphin, Ph.D., CEO of Avita Medical.

More than 3,500 patients have been treated with ReCell for treatment of burns, hypo- and hyper-pigmentation (e.g., Vitiligo, a common skin pigmentation disease), scar revisions (e.g., acne) and aesthetic skin rejuvenation procedures (e.g., wrinkle removal). Use of ReCell has been clinically demonstrated to improve outcomes, reduce morbidity, and reduce length of hospital stay and patient care costs.